Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review

Kaul, Isha; Amin, Ami; Rosenberg, Marta; Rosenberg, Laura; Meyer, Walter J.

doi:10.1016/j.burns.2017.07.018

Cited by 48 publications

(34 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…133,134 Oral gabapentin can be very effective in the treatment of neuropathic forms of itch (eg, brachioradial pruritus, notalgia paresthetica, and prurigo nodularis) and might also have some utility in treating itch associated with major burns, chronic kidney disease, or cutaneous lymphoma. 132,135,136 Gabapentin is generally started at night at low doses (300-600 mg) and gradually increased to achieve a total daily dose of 900 to 3600 mg (often taken in smaller doses 3 times per day). 132 If there is failure to respond or tolerate gabapentin, a trial of pregabalin might be reasonable (or vice versa).…”

Section: Anticonvulsantsmentioning

confidence: 99%

Itch: From mechanism to (novel) therapeutic approaches

Yosipovitch

Rosen

Hashimoto

2018

Journal of Allergy and Clinical Immunology

260

307

View full text Add to dashboard Cite

Itch is a common sensory experience that is prevalent in patients with inflammatory skin diseases, as well as in those with systemic and neuropathic conditions. In patients with these conditions, itch is often severe and significantly affects quality of life. Itch is encoded by 2 major neuronal pathways: histaminergic (in acute itch) and nonhistaminergic (in chronic itch). In the majority of cases, crosstalk existing between keratinocytes, the immune system, and nonhistaminergic sensory nerves is responsible for the pathophysiology of chronic itch. This review provides an overview of the current understanding of the molecular, neural, and immune mechanisms of itch: beginning in the skin, proceeding to the spinal cord, and eventually ascending to the brain, where itch is processed. A growing understanding of the mechanisms of chronic itch is expanding, as is our pipeline of more targeted topical and systemic therapies. Our therapeutic armamentarium for treating chronic itch has expanded in the last 5 years, with developments of topical and systemic treatments targeting the neural and immune systems.

show abstract

Section: Anticonvulsantsmentioning

confidence: 99%

Itch: From mechanism to (novel) therapeutic approaches

Yosipovitch

Rosen

Hashimoto

2018

Journal of Allergy and Clinical Immunology

260

307

View full text Add to dashboard Cite

show abstract

“…In this study, oral acitretin combined with topical pimecrolimus was used. In addition, gabapentin was prescribed to relieve severe itching . The combination of three drugs was obviously effective, which may inhibit multiple allergies induced by skin barrier injury.…”

Section: Discussionmentioning

confidence: 99%

Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of acitretin with gabapentin

Liang

Zhang

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome is a recently recognized syndrome caused by mutations in the desmoglein 1 (DSG1) and desmoplakin (DSP) genes. Only two cases of SAM‐DSP have been reported. We report on a 2‐year‐old girl presenting with pustular lakes within areas of erythema and large accumulations of intraepidermal neutrophils, which initially led to our misdiagnosis of generalized pustular psoriasis. No mutation was found in either the IL36RN or CARD14 genes by Sanger sequencing. The distinctive manifestations of erythroderma with severe itching, hypotrichosis, enamel defects, onychodystrophy, palmoplantar keratoderma and the crucial result of de novo missense mutation in exon 14 of the DSP gene (c.1828T>C, p.S610P) discovered by next‐generation sequencing finally confirmed the diagnosis of SAM syndrome. The eruptions significantly improved after a 4‐week treatment with oral acitretin and topical pimecrolimus. Oral gabapentin was prescribed simultaneously for 4 months, relieving her skin pruritus and suggesting that early treatment with pimecrolimus, acitretin and gabapentin for SAM‐DSP syndrome is effective. It may even inhibit multiple allergies induced by skin barrier injury. In this work we also review the clinical features, differential diagnoses and pathological manifestations of SAM‐DSP syndrome.

show abstract

“…However, the possibility of influencing the above symptoms is not limited to SNRIs (selective noradrenaline reuptake inhibitors) and SSRIs. In these processes, the influx of calcium ions is very important, which is inhibited by gabapentin and pregabalin [94] -active in the treatment of many symptoms induced by central sensitisation [95]. Until recently, the development of new SSRIs was inhibited due to reports of an increased risk of suicide in adolescents [96,97].…”

Section: Discussionmentioning

confidence: 99%

“…Jednak możliwości wpływania na powyższe objawy nie są ograniczone do leków z grup SSRI i inhibitorów wychwytu zwrotnego noradrenaliny (SNRI, selective noradrenaline reuptake inhibitors). W procesach tych istotną rolę odgrywa napływ jonów wapnia, hamowany przez gabapentynę i pregabalinę [94], które wykazują aktywność w leczeniu wielu objawów wywołanych ośrodkową sensytyzacją [95]. Do niedawna rozwój nowych leków przeciwdepresyjnych SSRI był zahamowany z powodu doniesień o podwyższonym ryzyku samobójstwa u młodzieży [96,97].…”

Section: Podsumowanieunclassified

Immunologia dla specjalistów medycyny paliatywnej. Rola receptorów Toll-like w wywoływaniu objawów choroby

Żylicz

2019

Palliat Med Pract

View full text Add to dashboard Cite

The human body is protected against pathogens originating from the external and internal world through a system of innate and acquired immunity, which work together both in healthy and sick subjects. The Toll-like receptors are located on the surface of microglia cells and are involved in the development of neurogenic inflammation, which subsequently leads to the emergence of many diseases and symptoms such as depression, fatigue, chronic and neuropathic pain, cough, constipation and pruritus. The Toll-like receptor activation is inhibited, inter alia, by antidepressants. It is probable that in the near future newer drugs will be known, which will inhibit the development of neurogenic inflammation more efficiently, in order to ensure a more effective treatment of symptoms resistant to standard pharmacotherapy.

show abstract

Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review

Cited by 48 publications

References 8 publications

Itch: From mechanism to (novel) therapeutic approaches

Itch: From mechanism to (novel) therapeutic approaches

Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of acitretin with gabapentin

Immunologia dla specjalistów medycyny paliatywnej. Rola receptorów Toll-like w wywoływaniu objawów choroby

Contact Info

Product

Resources

About